Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 13NIH 3INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 9Lymphoma, Follicular 4Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Graft vs Host Disease 2Ulcer 1Stomatitis 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Oral Ulcer 1Metastatic Castration-Resistant Prostate Cancer 1Melanoma 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Intestinal Obstruction 1Colitis, Ulcerative 1Colitis 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Methylprednisolone × Clear all
NCT06097364 2026-02-06

OLYMPIA-2

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
733 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡